Cost-effectiveness of lung transplantation in the Netherlands - A scenario analysis

被引:40
|
作者
Al, MJ
Koopmanschap, MA
van Enckevort, PJ
Geertsma, A
van der Bij, W
de Boer, WJ
TenVergert, EM
机构
[1] Erasmus Univ, Inst Med Technol Assessment, NL-3000 DR Rotterdam, Netherlands
[2] Univ Groningen Hosp, Off Med Technol Assessment, Groningen, Netherlands
[3] Univ Groningen Hosp, Dept Pulm Dis, Groningen, Netherlands
[4] Univ Groningen Hosp, Dept Cardiothorac Surg, Groningen, Netherlands
关键词
cost-effectiveness; cost utility; lung transplantation; microsimulation; scenario-analysis;
D O I
10.1378/chest.113.1.124
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objectives: To calculate cost-effectiveness of scenarios concerning lung transplantation in the Netherlands. Design: Microsimulation model predicting survival, quality of life, and costs with and without transplantation program, based on data of the Dutch lung transplantation program of 1990 to 1995. Setting: Netherlands, University Hospital Groningen. Patients: Included were 425 patients referred for lung transplantation, of whom 57 underwent transplantation. Intervention: Lung transplantation. Results: For the baseline scenario, the costs per life-year gained are G 194,000 (G=Netherlands guilders) and the costs per quality-adjusted life-year (QALY) gained are G 167,000. Restricting patient inflow ("policy scenario") lowers the costs per life-year gained: G 172,000 (costs per QALY gained: G 144,000). The supply of more donor lungs could reduce the costs per life-year gained to G 159,000 (G 135,000 per QALY gained; G1=US$0.6, based on exchange rate at the time of the study). Conclusions: Lung transplantation is an expensive but effective intervention: survival and quality of life improve substantially after transplantation, The costs per life-year gained are relatively high, compared with other interventions and other types of transplantation. Restricting the patient inflow and/or raising donor supply improves cast-effectiveness to some degree. Limiting the extent of inpatient screening or lower future costs of immunosuppressives may slightly improve the cost-effectiveness of the program.
引用
收藏
页码:124 / 130
页数:7
相关论文
共 50 条
  • [21] Cost-effectiveness of lung transplantation and its evolution: the Portuguese case
    Mendonca, Luis
    Perelman, Julian
    Rodrigues, Vanessa
    Fragata, Jose
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 (07): : 767 - 772
  • [22] Cost-effectiveness of lung transplantation and its evolution: the Portuguese case
    Luis Mendonça
    Julian Perelman
    Vanessa Rodrigues
    José Fragata
    The European Journal of Health Economics, 2014, 15 : 767 - 772
  • [23] Renal transplantation vs hemodialysis: cost-effectiveness analysis
    Perovic, Sasa
    Jankovic, Slobodan
    VOJNOSANITETSKI PREGLED, 2009, 66 (08) : 639 - 644
  • [24] MARROW TRANSPLANTATION, COST-EFFECTIVENESS ANALYSIS AND SETTING LIMITS
    WELCH, HG
    LEUKEMIA, 1993, 7 (07) : 1108 - 1111
  • [25] COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran
    Vaezi, Atefeh
    Meysamie, Alipasha
    VACCINES, 2022, 10 (01)
  • [26] WILL COST-EFFECTIVENESS ANALYSIS WORSEN THE COST-EFFECTIVENESS OF CARE
    HIMMELSTEIN, DU
    WOOLHANDLER, S
    BOR, DH
    CLINICAL RESEARCH, 1987, 35 (03): : A744 - A744
  • [27] Estimating the effectiveness and efficiency of USHIV prevention efforts using scenario and cost-effectiveness analysis
    Holtgrave, DR
    AIDS, 2002, 16 (17) : 2347 - 2349
  • [28] STAGING OF LUNG-CANCER - A COST-EFFECTIVENESS ANALYSIS
    HOUSTON, GA
    SANDERS, JA
    LITTLE, DD
    GRIFFITH, JE
    CLERICUZIO, C
    BALDUCCI, L
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1985, 8 (03): : 224 - 230
  • [29] Cost-effectiveness of pertussis booster vaccination in the Netherlands
    Rozenbaum, Mark H.
    De Cao, Elisabetta
    Postma, Maarten J.
    VACCINE, 2012, 30 (50) : 7327 - 7331
  • [30] COST-EFFECTIVENESS OF DIAGNOSING AXIAL SPONDYLOARTHRITIS IN THE NETHERLANDS
    Webers, C.
    Grimm, S.
    Van Tubergen, A.
    Van Gaalen, F. A.
    Van der Heijde, D.
    Joore, M.
    Boonen, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 510 - 511